RNS Number : 5269B
Genedrive PLC
02 June 2023

genedrive plc
("genedrive" or the "Company")

Equity Prepayment Facility drawdown

genedrive plc (LSE: GDR), the point of care molecular diagnostics company, today announces a first £300,000 draw down under the terms of the £5m Equity Prepayment Facility, which was previously announced by the Company on 31 March 2023. Investors have been granted 682,730 warrants equal to 40% of this drawdown divided by the Reference Price of 17.57648 pence. The exercise price of the warrants payable to the Company will be 140% of the Reference Price equating to 24.6071 pence.

Capitalised terms in this announcement shall, unless the context demands otherwise, bear the meanings given to such terms in the announcement of the Facility made via RNS on 31 March 2023.

For further information, please contact:

genedrive plc +44 (0) 161 989 0245
David Budd (CEO) / Russ Shaw (CFO)

Peel Hunt LLP - **Nominated Adviser, Joint Broker** +44 (0) 20 7148 8900
James Steel / Oliver Duckworth

finnCap Ltd - Joint Broker +44 (0) 20 7220 0500
Geoff Nash / George Dollemore

Walbrook PR - Financial PR & IR Adviser +44 (0) 20 7933 8780
Paul McManus / Anna Dunphy Or Genedrive@walbrookpr.com

About genedrive plc (http://www.genedriveplc.com)

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The company are currently developing a genetic test for CYP2C19 metaboliser status.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCUPUPPQUPWGGP